In recent years, the field of cancer immunotherapy has become a research hotspot, especially for immune checkpoint targeted therapy, such as cytotoxic lymphocyte-associated antigen-4 (CTLA-4) and programmed death receptor-l (PD-1)/programmed death ligand-1 (PD-L1) axis, and breast cancer susceptibility gene 1 (BRCA1) [3]. This evidence concerns the gene BRCA1 and cancer.